Founder mutations in BRCA1 and BRCA2 genes.

@article{Ferla2007FounderMI,
  title={Founder mutations in BRCA1 and BRCA2 genes.},
  author={Rita Ferla and Valentina Cal{\'o} and Sandra Cascio and Gaetana Rinaldi and Giuseppe Badalamenti and Ignazio Ugo Carreca and Eva Surmacz and Giuseppe Colucci and Viviana Bazan and Anna Russo},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2007},
  volume={18 Suppl 6},
  pages={
          vi93-8
        }
}
  • R. Ferla, V. Caló, A. Russo
  • Published 1 June 2007
  • Biology
  • Annals of oncology : official journal of the European Society for Medical Oncology
BRCA1 and BRCA2 germline mutations contribute to a significant number of familial and hereditary breast and/or ovarian cancers. The proportion of high-risk families with breast and/or ovarian cancer cases due to mutations in these tumor suppressor genes varies widely among populations. In some population, a wide spectrum of different mutations in both genes are present, whereas in other groups specific mutations in BRCA1 and BRCA2 have been reported with high frequency. Most of these mutations… 

Tables from this paper

The Contribution of BRCA1 and BRCA2 to Ovarian Cancer
BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile.
TLDR
The dramatic reduction of Amerindian population due to smallpox and wars with Spanish conquerors, a scarce population increase during 300 years, and the geographic position of Chile constituted a favorable scenario to establish founder genetic markers in the authors' population, resulting in the highest amount of founder mutations.
Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing
TLDR
Next‐generation sequencing (NGS) analysis of the entire coding regions of BRCA1 andBRCA2 in 135 breast and/or ovarian cancer patients suggests the utility of screening BRC a1 and BRCa2 mutations by NGS in clinical diagnosis.
Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2
TLDR
Estimates of penetrance (cancer risk) vary considerably depending on the context in which they were derived and have been shown to vary within families with the same BRCA1/2 mutation, suggesting there is no exact risk estimate that can be applied to all individuals with a BRCa1/ 2 mutation.
BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome
TLDR
The prevalence of BRCA rearrangements in 145 unrelated Brazilian individuals at risk for HBOC syndrome who had not been previously tested for BRCa mutations is determined and two families with false positive MLPA results were shown to carry a deleterious point mutation at the probe binding site.
Characterization of BRCA1/2 mutations in patients with family history of breast cancer in Armenia
TLDR
The results demonstrate the importance of screening of BRCA1 and BRCa2 gene variants in the Armenian population in order to identity specifics of mutation spectrum and frequencies and enable accurate risk assessment of hereditary breast cancers.
Mutational spectrum of BRCA1/2 genes in Moroccan patients with hereditary breast and/or ovarian cancer, and review of BRCA mutations in the MENA region
TLDR
The most frequent mutation identified in patients was the c.1310_1313delAAGA, BRCA2 (33%), and three other mutations seem more frequent in the Moroccan population (33%) of all reported patients, emphasize the importance of screening for BRC a1 and BRCa2 recurrent mutations in Moroccan patients.
Identification of low-penetrance alleles, genetic modifiers and mutation analysis in familial breast cancer cases
TLDR
The investigation of the two Fanconi Anemia genes PALB2 and SLX4 as breast cancer predisposing loci and the role of the CASP8 rs3834129 ins/del polymorphism as a genetic modifier in Italian BRCA1 and BrcA2 mutation carries is investigated, providing further knowledge on the susceptibility to this disease.
Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain)
TLDR
The findings may help design a first step recurrent mutation panel for screening high-risk breast and/or ovarian cancer families from this specific area, which largely differ from other areas of Spain.
...
...

References

SHOWING 1-10 OF 69 REFERENCES
High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area
TLDR
Mutational analysis of BRCA1/2 genes in 151 high-risk patients characterized the spectrum of gene alterations and demonstrated the dominant role of the BRCa1 c.5266dupC allele in hereditary breast and ovarian cancer.
Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population
  • A. Meindl
  • Biology
    International journal of cancer
  • 2002
TLDR
The main focus of this German‐wide multi‐center study was to establish a BRCA1/2 mutation profile and to determine family types with high frequencies of mutations in these genes and to provide strong evidence for further predisposing genes in the German population.
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
TLDR
The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age <50 years.
Germline mutations in the BRCA1 gene predisposing to breast and ovarian cancers in Upper Silesia population.
TLDR
The lowest frequency of the germline mutations was found in the healthy persons who had two or more relatives affected with breast or ovarian cancer, and most of the carriers of a germline mutation were observed among the patients who developed bilateral breast cancer.
A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques
TLDR
It is shown that the founder mutation BRCA1 c.3171ins5 has a great influence on western Swedish breast/ovarian cancer families along with a high number of mutations unique for the region.
Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
TLDR
Following the high proportion of Ashkenazi Jewish founder mutations in Slovak HBOC families, a pre-screening for at least 5382insC mutation in individuals at even moderate risk would be appropriate.
Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland
TLDR
Analysis of the cancer phenotypes showed differential ovarian cancer expression in families carrying mutations in the 5′ and 3′ ends of the BRCA1 gene, and earlier age of ovarian cancer onset in families with BRCa1 mutations compared with families withBRCA2 mutations.
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
TLDR
Carriers of the same mutation, from different families, shared similar haplotypes, indicating that the mutant alleles were likely to be identical by descent for a mutation in the founder population, which will facilitate carrier detection in French Canadian breast cancer and breast/ovarian cancer families.
High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia
TLDR
It is shown that BRCA mutations account for a substantial proportion of hereditary breast/ovarian cancer in Colombia, and the spectrum of mutations differed completely to that previously reported in Hispanic families of predominantly Mexican origin from Southern California suggesting that specific genetic risk assessment strategies for the different Hispanic populations in South America and in the United States need to be developed.
Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history
TLDR
The identification of founder BRCA1 and BRCa2 mutations in ovarian cancer cases unselected for family history can facilitate carrier detection when the expected yield of a comprehensive screen may be low.
...
...